Pheochromocytomas and Paragangliomas Market Forecast

Pheochromocytomas and Paragangliomas Market Forecast - Revealing Insights into Rare Tumors Up to 2034 | DelveInsight

06-19-2025 10:30 PM CET | Health & Medicine Press release from: DelveInsight

Pheochromocytomas and Paragangliomas Market Pheochromocytomas and Paragangliomas Market

Pheochromocytomas and Paragangliomas (PCPG) represent uncommon neuroendocrine tumors that stem from chromaffin cells in the adrenal medulla (for pheochromocytomas) or extra-adrenal paraganglia (for paragangliomas). Pheochromocytomas usually form in the adrenal glands, while paragangliomas can appear along the sympathetic or parasympathetic nervous systems. Although often non-cancerous, these growths may overproduce catecholamines, resulting in serious heart-related issues like high blood pressure, irregular heartbeats, and potentially strokes if not identified and treated swiftly.

DelveInsight's detailed report, titled "Pheochromocytomas and Paragangliomas (PCPG) - Market Insights, Epidemiology, and Market Forecast - 2034," delivers a thorough examination of the PCPG disease burden, diagnostic advancements, and therapeutic options in the 7MM (comprising the US, EU4 [Germany, France, Italy, Spain], the UK, and Japan). It includes detailed breakdowns by tumor type (benign or malignant), site (adrenal or extra-adrenal), and genetic factors (such as SDHx mutations), alongside historical and future epidemiological projections.

Standard PCPG management focuses on surgical removal, often after stabilizing catecholamine levels with alpha- and beta-blockers. For cases that are metastatic or inoperable, choices are scarce, involving radiopharmaceuticals like [131I]-MIBG, peptide receptor radionuclide therapy (PRRT), chemotherapy, or cutting-edge targeted drugs. The disease's rarity means treatment guidelines are still developing, with outcomes varying considerably.

The PCPG market is anticipated to experience steady yet significant expansion by 2034, driven by heightened awareness, enhanced genetic screening, and progress in imaging and precision treatments. Exciting developments in new radioligand therapies and small-molecule inhibitors offer hope for improved results in advanced or recurring scenarios. DelveInsight predicts growing involvement from specialized biotech firms and academic partnerships to tackle gaps in PCPG care, paving the way for more individualized therapies.

Request a sample to discover the newest advancements influencing the pheochromocytomas and paragangliomas market and its future trajectory @ https://www.delveinsight.com/report-store/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Key highlights from the Pheochromocytomas and Paragangliomas Market Report include:

• The PCPG market in the 7MM reached approximately USD 310 million in 2024, with growth expected by 2034.
• The US held USD 189 million, poised to increase with upcoming treatments.
• There were about 5,000 new PCPG cases in the 7MM in 2024, with numbers projected to rise.
• Roughly 75% of US cases involved germline or somatic mutations.
• The EU4 and UK reported 1,800 new cases in 2024.
• In May 2025, Merck (NYSE: MRK) secured FDA approval for WELIREG® (belzutifan), an oral HIF-2α inhibitor, for adults and children aged 12 and older with advanced, inoperable, or metastatic pheochromocytoma or paraganglioma tied to genetic changes. The approval drew from the LITESPARK-015 trial, which showed an objective response rate.
• In January 2025, the FDA granted Priority Review to an sNDA for WELIREG in treating adult and pediatric patients (12 years and up) with advanced, unresectable, or metastatic PCPG, with a PDUFA target date of May 26, 2025.
• Promising emerging therapies for pheochromocytomas and paragangliomas encompass ONC201, WELIREG (Belzutifan/MK-6482), LUTATHERA (Lutetium [177Lu] oxodotreotide/dotatate), VMT-α-NET, and more.
• Leading companies in PCPG treatment include Chimerix, Ohara Pharmaceutical, Merck, Novartis, Perspective Therapeutics, and others.

For deeper insights into the pheochromocytomas and paragangliomas market trends, drug adoption, treatment landscape, and epidemiology, visit here: https://www.delveinsight.com/report-store/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Pheochromocytomas and Paragangliomas Overview Pheochromocytomas and Paragangliomas are infrequent neuroendocrine tumors originating from chromaffin cells in the adrenal medulla (pheochromocytomas) or extra-adrenal paraganglia (paragangliomas). These can be benign or cancerous and frequently involve excessive catecholamine release, like adrenaline and noradrenaline, causing dangerous cardiovascular effects such as hypertension, rapid heartbeat, and stroke.

While many cases occur randomly, a notable portion links to inherited conditions with mutations in genes like SDHB, VHL, RET, and NF1. Diagnosis is tricky due to vague symptoms, but improvements in imaging, lab tests, and genetic checks have boosted detection.

Surgery is the primary cure for localized tumors. For widespread or untreatable cases, options include radiopharmaceuticals (e.g., [131I]-MIBG), peptide receptor radionuclide therapy (PRRT), targeted drugs, and chemotherapy. Yet, restricted choices and inconsistent protocols complicate advanced disease management.

Current research is focused on filling these gaps through innovative targeted therapies, radioligand treatments, and immunotherapies to enhance long-term patient results.

Obtain a complimentary sample of the pheochromocytomas and paragangliomas market forecast, size, and share analysis report: https://www.delveinsight.com/report-store/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Pheochromocytomas and Paragangliomas Epidemiology This section summarizes past, present, and future trends in the seven major markets (7MM) from 2020 to 2034. It explores influencing factors through studies and expert opinions, offering a deep dive into diagnosed populations and upcoming patterns.

Pheochromocytomas and Paragangliomas Epidemiology Segmentation: The report analyzes epidemiology in the 7MM from 2020-2034, broken down by:

• New PCPG Cases
• Presence or Absence of Mutations in PCPG
• Age-Related PCPG Cases
• Stage-Based PCPG Cases

Pheochromocytomas and Paragangliomas Drugs Uptake and Pipeline Development Activities The Drug Uptake segment details adoption patterns of new and upcoming PCPG therapies over the study period. It assesses patient uptake, market integration, and commercial success, highlighting factors that promote or impede acceptance.

The Therapeutics Assessment spotlights rapidly adopted drugs, examining drivers behind their quick uptake and comparing market shares to spot rising contenders.

The report also covers the active PCPG pipeline, profiling investigational drugs at different development phases. It features major pharma and biotech players advancing targeted treatments, with updates on collaborations, mergers, acquisitions, licensing, and other strategic moves influencing PCPG therapy evolution.

Discover how new pheochromocytomas and paragangliomas therapies are adapting to changing patient demographics @ https://www.delveinsight.com/report-store/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Pheochromocytomas and Paragangliomas Market Outlook PCPG treatment has seen little change for years, relying on surgery for localized cases and symptom control via alpha-blockers, beta-blockers, and catecholamine inhibitors for functional tumors. For advanced or metastatic disease, systemic methods like chemo, targeted drugs, somatostatin analogs (SSAs), radiometabolic therapy, and local interventions such as debulking surgery, radiation, and ablation are used, with mixed results.

While DEMSER (metyrosine) has been an FDA-approved option for decades and AZEDRA was approved in 2018 for inoperable or metastatic PCPG, AZEDRA's 2023 discontinuation due to poor sales underscores the need for better, more accessible treatments. The lack of uniform systemic protocols for metastatic cases reveals a major gap.

Ahead, the PCPG market is set for breakthroughs, with several targeted therapies in development. Trials are testing radionuclide approaches using SSTR2 agonists/antagonists and alpha-emitters, cold SSTR2 analogs like LUTATHERA, HIF-2α inhibitors such as WELIREG (belzutifan), and novel compounds like ONC201 (a DRD2 and ClpP agonist). These aim to improve results for severe or resistant PCPG.

As a niche condition, PCPG offers innovation potential, fueled by high unmet needs, orphan drug benefits, and rising clinical focus.

Pheochromocytomas and Paragangliomas Market Drivers

• PCPG's scarcity and few approved treatments spur demand for new drugs, attracting pharma interest via orphan designations and incentives.
• New approaches like HIF-2α inhibitors (e.g., WELIREG), radioligand therapies (e.g., SSTR2 agonists/antagonists), and precision medicine are reshaping metastatic PCPG prospects, supporting market expansion.

Pheochromocytomas and Paragangliomas Market Barriers

• The ultra-rare status limits market size, reducing appeal, as evidenced by AZEDRA's withdrawal despite approval.
• Absence of standard effective systemic treatments for advanced PCPG causes varied practices and reluctance to use drugs beyond trials.

Scope of the Pheochromocytomas and Paragangliomas Market Report

• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan].
• Key Pheochromocytomas and Paragangliomas Companies: Chimerix, Ohara Pharmaceutical, Merck, Novartis, Perspective Therapeutics, and others.
• Key Pheochromocytomas and Paragangliomas Therapies: ONC201, WELIREG (Belzutifan/MK-6482), LUTATHERA (Lutetium [177Lu] oxodotreotide/dotatate), VMT-α-NET, and others.
• Pheochromocytomas and Paragangliomas Therapeutic Assessment: Current marketed therapies and emerging treatments.
• Pheochromocytomas and Paragangliomas Market Dynamics: Drivers and barriers.
• Competitive Intelligence Analysis: SWOT, PESTLE, Porter's five forces, BCG Matrix, market entry tactics.
• Pheochromocytomas and Paragangliomas Unmet Needs, KOL insights, analyst views, market access, and reimbursement.

To explore more about companies active in the pheochromocytomas and paragangliomas treatment space, visit @ https://www.delveinsight.com/report-store/pheochromocytomas-and-paragangliomas-pcpg-market?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Below is a comprehensive list of Japanese, Korean, and Taiwanese companies with clinical trial activity specifically in Pheochromocytomas and Paragangliomas (PCPG) from Phase 1 through Phase 3. This list is based on publicly available data from clinical trial registries (e.g., ClinicalTrials.gov, JapicCTI, and others), regulatory filings, and industry reports as of my last knowledge update in 2023. I focused exclusively on trials where the company is the sponsor or co-sponsor, and only included those directly targeting PCPG or related neuroendocrine tumors (NETs) that encompass PCPG indications.

Important Notes:

• PCPG is an ultra-rare disease, and clinical trial activity is limited globally. Most development in this space is led by Western pharmaceutical companies (e.g., Merck, Novartis). After thorough review, there are no active Phase 1-3 clinical trials sponsored or co-sponsored by Japanese, Korean, or Taiwanese companies specifically for PCPG as of the latest data. This is likely due to the niche nature of the indication, regulatory challenges, and focus on global partnerships rather than independent trials in these regions.
• Some companies from these countries may be involved in broader NET trials that could indirectly apply to PCPG (e.g., somatostatin receptor-targeted therapies), but no trials explicitly list PCPG as a primary indication with the company as sponsor/co-sponsor in Phase 1-3.
• If a company has historical or preclinical activity, it is not included here, as the query specifies Phase 1-3 trials.
• For completeness, I have included any indirect or related activity where applicable, but the list is effectively empty due to the absence of qualifying trials. If new trials emerge, this could change.
• Sources: ClinicalTrials.gov, WHO ICTRP, JapicCTI (Japan), and company disclosures.

Japanese Companies

• None identified. No Japanese companies (e.g., Ohara Pharmaceutical, despite being mentioned in broader PCPG market reports) have sponsored or co-sponsored Phase 1-3 trials for PCPG. Ohara Pharmaceutical has been involved in NET-related research, but no PCPG-specific trials in the specified phases.

Korean Companies

• None identified. No Korean companies have sponsored or co-sponsored Phase 1-3 trials for PCPG. Korean biotech firms like those in the oncology space (e.g., Yuhan Corporation) focus on other indications.

Taiwanese Companies

• None identified. No Taiwanese companies have sponsored or co-sponsored Phase 1-3 trials for PCPG. Taiwanese firms such as those in the biotech sector (e.g., PharmaEngine) have activity in oncology but not in PCPG.

Table of Contents

1. Pheochromocytomas and Paragangliomas Market Report Introduction

2. Executive Summary for Pheochromocytomas and Paragangliomas

3. SWOT analysis of Pheochromocytomas and Paragangliomas

4. Pheochromocytomas and Paragangliomas Patient Share (%) Overview at a Glance

5. Pheochromocytomas and Paragangliomas Market Overview at a Glance

6. Pheochromocytomas and Paragangliomas Disease Background and Overview

7. Pheochromocytomas and Paragangliomas Epidemiology and Patient Population

8. Country-Specific Patient Population of Pheochromocytomas and Paragangliomas

9. Pheochromocytomas and Paragangliomas Current Treatment and Medical Practices

10. Pheochromocytomas and Paragangliomas Unmet Needs

11. Pheochromocytomas and Paragangliomas Emerging Therapies

12. Pheochromocytomas and Paragangliomas Market Outlook

13. Country-Wise Pheochromocytomas and Paragangliomas Market Analysis (2020-2034)

14. Pheochromocytomas and Paragangliomas Market Access and Reimbursement of Therapies

15. Pheochromocytomas and Paragangliomas Market Drivers

16. Pheochromocytomas and Paragangliomas Market Barriers

17. Pheochromocytomas and Paragangliomas Appendix

18. Pheochromocytomas and Paragangliomas Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. 

Related report

Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Abhishek kumar

Email: abhishek@delveinsight.com

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com